---
title: "mTOR inhibitors-of-renal-cell-carcinoma"
date: "2024-01-03 11:11:04"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ±ä¾†è‡ªï¼š[[renal-cell-carcinoma]]

# mTOR inhibitors-of-renal-cell-carcinoma

- 1Â° endpoint(s) listed below include PFS,
- OS at interim analysis Class S/E: Stomatitis,
- fatigue,
- rash,
- edema,
- pneumonitis,
- hyperglycemia,
- hyperlipidemia,
- â†“ WBC,
- â†“ PLT

Everolimus (Lancet 2008;372:449) vs. placebo: PFS: 4 mos vs. 1.9 mos (HR: 0.30, P <0.0001)
Temsirolimus (NEJM 2007;356:2271) vs. IFNÎ±: OS: 10.9 mos vs. 7.3 mos (HR: 0.73, P = 0.008)

### Siblings

- [[Epidemiology-of-renal-cell-carcinoma]]
- [[Histology and molecular biology-of-renal-cell-carcinoma]]
- [[Hereditary RCC and germline testing-of-renal-cell-carcinoma]]
- [[Clinical presentation-of-renal-cell-carcinoma]]
- [[Staging (TNM classification) and prognosis-of-renal-cell-carcinoma]]
- [[Treatment principles-of-renal-cell-carcinoma]]
- [[Systemic therapy for metastatic clear cell RCC]]
- [[Second-line therapies-of-renal-cell-carcinoma]]
- [[Combined-modality therapies-of-renal-cell-carcinoma]]
- [[Tyrosine kinase inhibitors-of-renal-cell-carcinoma]]
- [[Immunotherapies-of-renal-cell-carcinoma]]
- [[mTOR inhibitors-of-renal-cell-carcinoma]]
- [[Non-clear cell histology-of-renal-cell-carcinoma]]
